<DOC>
	<DOCNO>NCT01334567</DOCNO>
	<brief_summary>The purpose study offer subject center Taiwan successfully complete 168 week treatment study GS US 174-0108 access treatment tenofovir DF three additional year ( 144 week ) . Subjects follow per local standard care . Serious adverse event ( SAEs ) , drug accountability patient disposition record .</brief_summary>
	<brief_title>Rollover Protocol Continued Access Tenofovir Disoproxil Fumarate ( TDF ) Subjects Taiwan</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Subjects must meet follow inclusion criterion eligible participation study . Complete end study visit procedure GS US 1740108 study . Willing able provide write informed consent . A negative pregnancy test require female subject end study visit ( i.e. , screen visit study GSUS1740141 ) GS US 1740108 ( unless surgically sterile great two year postmenopausal ) All sexually active female subject post menopausal , surgically sterile childbearing potential must agree use highly effective method contraception heterosexual intercourse throughout study . Male subject sexually active require use barrier contraception ( condom spermicide ) heterosexual intercourse study completion . â€¢ Not Applicable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>